Michael
Aug 30, 2022 4 tweets 2 min read Read on X
While GLP1 therapies primarily exert their weight loss effect through a reduction in food intake, I’m increasingly convinced the most important mechanism behind the decrease in Ein is an attenuation of motivation-reward. I suspect homeostatic modulation plays a smaller role LT.
Mind you that this is speculative, but as my friend, @DavidMacklinMD often says, all roads lead to hedonic hunger. Do you WANT to eat? Are you compelled? Most people describe having better control, less interest, and a lack of compulsion while on GLP1s. It’s hedonics!
@MichaelMossC does a brilliant job describing the history behind the modern food environment and how it hijacks our biology in #Hooked. GLP1 therapies seem to turn off the feedback systems that drive a lot of the conditioned wanting & eating. Anticipatory drive improves as well.
It also makes me wonder if GLP1 therapies can be leveraged in addiction? There are so many overlapping neural circuits, and if it turns out this is the primary mechanism, then it stands to reason that GLP1RAs may in fact be a whole new class of therapies for SUD and addiction.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Michael "Mike" Albert, MD

Michael

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @MichaelAlbertMD

Aug 6, 2023
1/ WHAT YOU NEED TO KNOW ABOUT THE QUALITY OF WEIGHT LOSS. 🧵 Image
2/ When you lose weight, you don’t just lose from fat but also from other body compartments, including lean tissues. Image
3/ Why should you care about where the weight comes from?
Excess loss from specific lean tissues is associated with many adverse health outcomes: reduced QoL, osteoporosis, sarcopenia/frailty, decreased ability to perform ADLs, etc.
Read 19 tweets
Feb 19, 2023
1/ Are lean mass losses a real concern with GLP1 meds?
peterattiamd.com/the-downside-o…
🧵
2/ Simply, yes. And it is a concern any time you lose significant wt. I would remind people that human outcomes are the most informative, as physical functioning scores and QoL improved in STEP trials & SURMOUNT-1. However, the LT health impacts of LM loss need to be monitored.
3/ Fortunately, we have some high-quality data from Lundgren et al., 2021.

👉Structured Exercise + Liraglutide (GLP-1RA) led to FM loss and LM gain.
Read 6 tweets
Dec 22, 2022
1/ Merry 🧵-mas
---
WHY DECADES OF "EAT LESS AND MOVE MORE" WAS TERRIBLE ADVICE

For starters, remember semaglutide? How could you not? Journalists have written 1000+ celebrity weight loss stories on it.
2/ If you're familiar with semaglutide, you may know it is FDA-approved for treating obesity and chronic weight management under the brand name "WE-GOVY."
3/ Our story begins with the STEP Trials, a slate of phase 3 clinical trials that served as clinical validity for a novel drug platform for obesity.
Read 10 tweets
Nov 11, 2022
NASH Treatment Strategies:
1) Reduce Adiposity
2) Improve adipose tissue function (more difficult; PPARg agonists)
Pts w/ F2 or F3 fibrosis, SEMA 0.4 mg SQ Q at 0.4 mg was superior to placebo for resolution of NASH w/o worsening of fibrosis after 72 wks of tx, with 59% of the pts in the 0.4-mg group having a response, as compared with 17%. (OR, 6.87; 95% CI, 2.60 to 17.63; P<0.001)
Read 9 tweets
Nov 10, 2022
Treat-to-target for NAFLD/NASH:
🔑 is ≥ 10% weight loss.
journal-of-hepatology.eu/article/S0168-… Image
Bariatric surgery is exceedingly effective for people with obesity and NASH.
Aminian et al., JAMA. 2021.
jamanetwork.com/journals/jama/… Image
Mediterranean diet adherence is inversely associated with liver steatosis, 10-yr ASCVD risk, and NAFLD-associated incident T2DM.
linkinghub.elsevier.com/retrieve/pii/S…
Read 5 tweets
Nov 2, 2022
1/DAY 1 of #OW2022 in the books.

My highlight 🧵:
2/The Effect of COVID on Clinical Research by Drs. Laughlin and Evans:
—Significant increase in new onset diabetes
—A lot of COVID specific research for years to come
—COVID19 disproportionately impacted female scientists, parents and caregivers #OW2022
3/Update on the Use of Genetic Information to Tailor Obesity Treatment by Dr. Kaplan:
—People respond uniquely to treatments
—Genetic info can be used to predict treatment response and risk for weight gain over one’s life
—Precision genetic research IS EARLY #OW2022
Read 12 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(